Orient Pharma CoROCO:4166 +5.02%56 Days Payable is 33.95 as of Dec. 2025, which is 3% above its 10-year median of 32.82. GuruFocus rates ROCO:4166 with a GF Score™ of 56/100 and a GF Value™ of NT$45.09 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 922 Drug Manufacturers companies, Orient Pharma Co ranks worse than 86.33% on this metric.
The historical rank and industry rank for Orient Pharma Co's Days Payable or its related term are showing as below:
ROCO:4166'
s Days Payable Range Over the Past 10 Years
Min: 14.4 Med: 32.82 Max: 50.89
Current: 34.7
During the past 13 years, Orient Pharma Co's highest Days Payable was 50.89. The lowest was 14.40. And the median was 32.82.
ROCO:4166's Days Payable is ranked worse than 86.33% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.61
vs ROCO:4166: 34.70
Orient Pharma Co's Days Payable
increased
from Dec. 2024 (22.68) to Dec. 2025 (33.95).
It may suggest that Orient Pharma Codelayed paying its suppliers.
Orient Pharma Co Days Payable Related Terms
Orient Pharma Co Days Payable Historical Data
* Premium members only.
The historical data trend for Orient Pharma Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orient Pharma Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Orient Pharma Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Orient Pharma Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orient Pharma Co (ROCO:4166) has a Days Payable of 33.95 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Orient Pharma Co and its competitors. This is near median its historical median of 32.82. Over the past decade, Orient Pharma Co's Days Payable has ranged from 14.40 to 50.89. According to the industry distribution chart, Orient Pharma Co ranks #796 out of 922 companies in the Drug Manufacturers industry, placing it in the top 86.3%.
Is Orient Pharma Co's Days Payable too high?
Orient Pharma Co's current Days Payable of 33.95 is near median its 10-year median of 32.82. Over the past 10 years, this metric has ranged from a low of 14.40 to a high of 50.89. The Drug Manufacturers industry median Days Payable is 90.61. Orient Pharma Co's value of 33.95 is 62.5% below this industry median. Based on the distribution chart, Orient Pharma Co ranks #796 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Orient Pharma Co has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orient Pharma Co ranks #796 out of 922 companies for Days Payable. This places Orient Pharma Co in the lower half of its industry. The industry median Days Payable is 90.61. Orient Pharma Co's value of 33.95 is 62.5% below this benchmark. Historically, Orient Pharma Co's own Days Payable has ranged from 14.40 to 50.89 over the past decade. While the company's 10-year median is 32.82 vs. the industry median of 90.61, Orient Pharma Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.61, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orient Pharma Co's current Days Payable of 33.95 is 62.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Orient Pharma Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orient Pharma Co's current Days Payable is 33.95, which is near median its own 10-year median of 32.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$45.09, compared to a current price of NT$27.20 — trading 39.7% below its estimated fair value. The current Days Payable is 33.95, which is near median its 10-year median of 32.82 and 62.5% below the Drug Manufacturers industry median of 90.61. Orient Pharma Co's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current Days Payable is 33.95 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?
Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued.
The current stock price of NT$27.20 is trading 39.7% below its estimated GF Value™ of NT$45.09.
GuruFocus considers Orient Pharma Co to be Significantly Undervalued.
Key valuation signals for ROCO:4166:
Days Payable: 33.95 (near median its 10-year median of 32.82)
GF Value™: NT$45.09 vs. price of NT$27.20 (39.7% below fair value)
Industry Position: 62.5% below the Drug Manufacturers median (#796 of 922)
No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
56GF Score
Get the complete analysis for ROCO:4166
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4166 has been successfully added to your 
